SCHEMBL5415230

SCHEMBL5415230

CCOC(=O)Nc1cnc(Nc2ccc(Cl)c(Cl)c2)nc1NC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 7/20 0.48
▸ KDR P35968 7/20 0.48
▸ STK17A Q9UEE5 2/20 0.47
▸ KMT2A Q03164 3/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ HPGD P15428 1/20 0.46
▸ BRD4 O60885 2/20 0.45
▸ MAPK13 O15264 1/20 0.45
▸ MAPK12 P53778 1/20 0.45
▸ MAPK11 Q15759 1/20 0.45
▸ MAPK14 Q16539 1/20 0.45
▸ STK17B O94768 1/20 0.44
▸ HDAC3 O15379 1/20 0.44
▸ HDAC1 Q13547 1/20 0.44
▸ HDAC2 Q92769 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.44
▸ MAPT P10636 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ SYK P43405 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5418427 0.89 HDAC3 (0.47) EGFRKDRSTK17ABRD4STK17B
SCHEMBL5409821 0.87 MEN1 (0.53) EGFRKMT2AALDH1A1BRD4MAPT
SCHEMBL5414078 0.86 HTT (0.47) STK17AKMT2AALDH1A1HPGDBRD4
SCHEMBL5413822 0.86 CYP3A4 (0.53) EGFRSTK17AKMT2ABRD4MAPK14
SCHEMBL5418319 0.85 EGFR (0.45) EGFRKDRSTK17ABRD4STK17B
SCHEMBL5415948 0.85 HDAC3 (0.49) EGFRSTK17AKMT2ABRD4STK17B
SCHEMBL5415300 0.84 BRD4 (0.46) EGFRSTK17AALDH1A1BRD4MAPK13
SCHEMBL5408068 0.84 LRRK2 (0.47) EGFRSTK17AKMT2ASTK17BHDAC3
SCHEMBL5408198 0.84 HDAC3 (0.48) STK17AALDH1A1BRD4STK17BHDAC3
SCHEMBL5415421 0.84 STK17A (0.48) STK17ABRD4STK17BHDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 — — US disclosed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 — — US disclosed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134838-A1 Trisubstituted pyrimidines APP, PSEN1, BACE1 EGFR 3316/4885KDR 3267/4885STK17A 3301/4885
US-20050090486-A1 Trisubstituted pyrimidines APP, BACE1, PSEN1 EGFR 3952/4885KDR 3178/4885STK17A 3456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback